4Soon YY, Stockier MR, Askie LM, ct 81. Duration d chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol , 2009, 27:3277- 3283. 被引量：1
5Folkman J. Antiangiogenesis in cancer thcrapy:endostatin and its mechanisms of action. Exp Cell Res, 2006, 312:594-607. 被引量：1
6Sandier A, (;ray B, Perry MC, et al. Paclitaxel-earboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355:2542-2550. 被引量：1
7Reek M, van Pawel J, Zatloukal P, et al. Overall survival with eisplatin-gemcitabine and bevaeizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase m trial(AVAil). Ann Oncol, 2010, 21:1804- 1809. 被引量：1
8Ulahannan SV, Brahmer JR. Antiangiogenie agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest, 2011,29:325-337. 被引量：1
9Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res, 2006, 12(24): 7232-7241. 被引量：1
10Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 2007- 7(3): 169-181. 被引量：1
